Get startedLog in
    Picture of Swedish Orphan Biovitrum AB (publ) logo

    SOBI — Swedish Orphan Biovitrum AB (publ) News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: SOBI: Tryngolza (Olezarsen) Approved In EU For Familial Chylomicronemia Syndrome

    Picture of Swedish Orphan Biovitrum AB (publ) logoSwedish Orphan Biovitrum AB (publ)
    19/09/2025 07:46
    Sept 19 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST:

TRYNGOLZA ® (OLEZARSEN) APPROVED IN THE EUROPEAN UNION FOR FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS)

APPROVAL IS BASED ON POSITIVE DATA FROM PHASE 3 BALANCE STUDY

TRYNGOLZA SHOWED A FAVOURABLE SAFETY AND TOLERABILITY PROFILE

HAS EXCLUSIVE RIGHTS TO COMMERCIALIZE TRYNGOLZA IN COUNTRIES OUTSIDE U.S., CANADA AND CHINA

Source text: ID:nPreRHVZDa

Further company coverage: SOBIV.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Swedish Orphan Biovitrum AB (publ)

    See all news